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Abstract
Background—Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants, 
occurring from anthropogenic and natural sources. Several animal studies have reported a positive 
association of PAHs with inflammation. However, it is not clear if lower background exposure to 
PAHs is associated with inflammation in humans, independent of smoking, a major source of 
PAHs.
Methods—We examined participants from the National Health and Nutrition Examination 
Survey 2001– 2002, 2003–2004, and 2005–2006. Our exposures of interest were eight urinary 
monohydroxy polycyclic aromatic hydrocarbon biomarkers. Our outcomes were serum markers of 
inflammation; C-reactive protein (CRP) (≤10 mg/L) and total white blood cell (WBC) count 
(4000–12,000 cells/µL).
Results—Compared to participants with summed biomarkers of low-molecular weight (LMW) 
PAHs in the lowest quartile, the multivariable odds ratios (95% confidence interval) of high serum 
CRP (≥3 mg/L) and high total WBC count (defined as at or above the 95 percentile of total WBC 
distribution) among participants in the highest exposure quartile were 1.77 (1.13, 2.76) and 1.34 
(1.12, 1.60) respectively. Urinary 1-hydroxypyrene, the biomarker of the higher molecular weight 
pyrene, was positively associated with total WBC count, and to lesser extent with serum CRP. In 
subsequent analyses, the positive association between LMW PAHs and serum CRP and total 
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WBC count was found to be present within the stratified subgroups, independent of smoking and 
other potential confounders. The positive association was more evident among adult males when 
compared to females.
Conclusions—Urinary PAH biomarkers were found to be positively associated with serum CRP 
and total WBC count independent of smoking and other potential confounders. The association 
was more evident in men.
Keywords
Polycyclic aromatic hydrocarbons; Inflammation; Serum C-reactive protein; Total white blood 
cell count; NHANES
1. Introduction
Systemic inflammation is considered a key risk factor for atherosclerosis and subsequent 
development of cardiovascular disease (CVD) (Tracy, 1998). Several studies have reported a 
positive association between baseline elevations of C-reactive protein (CRP), a serum 
inflammatory maker, and future risk of CVD (Ridker et al., 1997; Ridker et al., 1998). 
Clinical and public health groups have recommended serum CRP levels to be used as a CVD 
risk stratifying tool (Yeboah, 2012). In addition, elevations in total white blood cells (WBC) 
count within the normal range (4000–12,000 cells/µL) were found to be independently 
associated with increased risk of CVD and have been proposed as an alternate serum 
inflammatory marker (Kannel et al., 1992).
Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants composed of 
fused aromatic rings (Talaska et al., 1996; Angerer et al., 1997; Warshawsky, 1999). PAHs 
may occur in oil, coal, and tar deposits, and are produced as byproducts of indoor and 
outdoor fuel burning (Liu et al., 2008; Achten and Hofmann, 2009). PAHs can be also found 
in contaminated water and in food as a result of food processing, preparation, and cooking 
(Ramesh et al., 2004; Šimko, 2005). Further, exposure to PAHs is markedly increased by 
cigarette smoking. Several in-vitro and animal studies have reported a positive association 
between exposure to PAHs and systemic inflammation (Albert et al., 1977; Penn et al., 
1981; Curfs et al., 2005; Jeng et al., 2011). However, it is not clear if the lower background 
exposure to PAHs is associated with inflammatory effects in humans in the general 
population.
In this context, we examined the association of eight urinary biomarkers of PAHs, the 
monohydroxy-PAHs (OH-PAH), with serum CRP and total WBC count in a nationally 
representative sample of United States (US) adults. Since exposure to active smoking and 
second hand cigarettes smoke are major sources of PAHs, we sought to determine if this 
relationship was independent of serum cotinine, self-reported cigarettes smoking status, and 
other potential confounders.
Due to the multiple sources of PAHs in the environment, exposure to a single PAH 
compound is implausible. Metabolism, and consequently health effects of exposure to 
multiple PAHs were found to be different from that of exposure to an individual PAH 
compound (Olatubi, 2005). Enzyme competition was evident in the metabolism of PAH 
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mixtures, changing significantly the metabolism patterns from that of individual PAHs 
(Olatubi, 2005). Therefore in the current study, and similar to analytical strategies employed 
by previous authors (Xia et al., 2009), we created a summed variable as a measure of 
cumulative exposure to multiple low molecular weight PAHs simultaneously.
2. Methods
2.1. Study population
The present study is based on merged data from the 2001–2002, 2003–2004 and 2005–2006 
National Health and Nutrition Examination Survey (NHANES). Detailed description of 
NHANES study design and methods are available elsewhere (Centers for Disease Control 
and Prevention (CDC). National Center for Health Statistics (NCHS) 2001). NHANES 
included a stratified multistage probability sample representative of the civilian non-
institutionalized US population. Selection was based on counties, blocks, households and 
individuals within households, and included oversampling of non-Hispanic Blacks and 
Mexican Americans in order to provide stable estimates of these groups. Out of 31,509 
participants in NHANES 2001–2006, there were 11,512 who were 20–65 years of age. 
Urinary PAH biomarkers were only measured in a subsample of individuals. The subsample 
is nationally representative, but with a smaller analytic sample size.
We excluded participants with missing information on serum CRP or with CRP levels >10 
mg/L, indicating potential underlying non-cardiovascular causes of inflammation (Pearson 
et al., 2003). We further excluded participants with missing information on serum cotinine 
level, or other covariates included in the final CRP model. Similarly, to minimize the 
confounding effect of infection, only subjects with a WBC count within the normal range 
(4000–12,000 cells/µL) were included in the final WBC analysis. We also excluded 
participants with missing information on total WBC count, or other covariates included in 
the final model.
2.2. Main outcome of interest: serum inflammatory markers
2.2.1. High sensitivity serum C-reactive protein—Serum CRP was measured using 
latex-enhanced nephelometry. Details of the laboratory collection, processing, and analysis 
are available in the laboratory procedures manual (Centers for Disease Control and 
Prevention (CDC). National Center for Health Statistics (NCHS) 2001). High CRP level was 
defined as values ≥3 mg/dL, consistent with American Heart Association/Centers for 
Disease Control & Prevention (AHA/CDC) guidelines for identifying subjects with high risk 
of CVD (Pearson et al., 2003).
2.2.2. Total white blood cell count within normal values—The methods used to 
derive WBC count are based on the Beckman Coulter method of counting. High WBC count 
was defined as values at or above the 95th percentile of the total WBC count distribution, 
consistent with previous studies examining the association between total WBC count within 
normal ranges and CVD risk (Kannel, 1992; Twig et al., 2012).
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2.3. Main exposure: urinary levels of monohydroxy-PAH
Urine specimens collected during the clinical exam portion of the survey were processed, 
stored, and shipped to the Division of Environmental Health Laboratory Sciences, National 
Center for Environmental Health, Centers for Disease Control and Prevention for analysis. 
The specific analytes measured in this study were monohydroxy-PAH (OH-PAH). By 
evaluating these analytes in urine, a measurement of the body burden from PAH exposure is 
obtained (Castano-Vinyals et al., 2004). The procedure involves enzymatic hydrolysis of 
urine, extraction, derivatization and analysis using capillary gas chromatography combined 
with high resolution mass spectrometry (GC-HRMS). Detailed specimen collection and 
processing instructions are discussed in the NHANES Laboratory/Medical Technologists 
Procedures Manual (LPM).
Seven LMW PAH urinary biomarkers, naphthalene biomarkers; 1-hydroxy-naphthalene, 2-
hydroxynaphthalene, fluorene biomarkers; 2-hydroxyfluorene, 3-hydroxyfluorene, 
phenanthrene biomarkers; 1-hydroxyphenanthrene, 2-hydro-xyphenanthrene, 3-
hydroxyphenanthrene and 1-hydroxypyrene, the biomarker of the higher molecular weight 
PAH pyrene, were consistently available in NHANES 2001–2006. All analytes were 
measured in the same unit; ng/L. Urinary OH-PAH were corrected for urinary creatinine 
concentration, a urinary marker of kidney function to adjust for urinary dilution (Barr et al., 
2005). Urinary levels of OH-PAH (ng/L) were divided by urinary creatinine level (mg/dL) 
multiplied by 0.01; [(ng/L)/ (mg/dL× 0.01)] and expressed as nanogram per gram of 
creatinine (ng/g creatinine).
2.4. Exposure measurements
Information on age, gender, race/ethnicity, alcohol intake, income, diabetes and cigarette 
smoking were obtained from a standardized questionnaire during a home interview. Alcohol 
consumption was categorized into none and alcohol drinker. Income-poverty ratio (income/
poverty guideline) was used as a measure of the socioeconomic status. The Department of 
Health and Human Services' poverty guidelines were used as the poverty measure to 
calculate this ratio. Cigarettes smoking status was categorized into never smokers (smoked < 
100 cigarettes during their lifetime), former smokers (smoked ≥100 cigarettes during their 
lifetime and currently not smoking), current smokers (smoked ≥100 cigarettes during their 
lifetime and currently smoking). Information on anthropometric, physical and laboratory 
components were obtained during the medical examination center examination. Body mass 
index (BMI) was calculated as weight in kilograms divided by height in meters squared. 
Seated blood pressure was measured using a mercury sphygmomanometer according to the 
American Heart Association and recommendations (Chaturvedi, 2004). Up to 3 
measurements were averaged for blood pressure.
2.5. Statistical analysis
Urinary levels of OH-PAH were analyzed both as continuous as well as categorical 
variables. For analysis as continuous variables, urinary OH-PAH levels were log-
transformed as a result of their skewed distribution. Weighted Pearson correlation 
coefficients between individual OH-PAH were calculated to evaluate the correlations 
between pairwise combinations of all eight urinary metabolites. We created a summed 
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LMW PAH biomarkers variable by summing urinary levels of metabolites of the low 
molecular weight PAHs (naphthalene, fluorene and phenanthrene).
We ran linear regression models to calculate the multivariable change and 95% confidence 
interval (CI) in serum CRP and total WBC count with increasing individual and additive 
urinary OH-PAH levels. In addition, we ran logistic regression models to calculate the 
multivariable odds ratio (OR) and 95% CI of high serum CRP (≥3 mg/L) and total WBC 
count in the 95th percentile, for each higher urinary OH-PAH quartile by using the lowest 
quartile as the referent. Variables were included in the model if they satisfied a plausible 
association with the main exposure/outcome. In addition, we used stepwise adjustment to 
identify the variables that could predict changes in serum CRP as well as total WBC count. 
Inclusion and retention of variables were allowed at a 10% change of odds ratio after 
adjusting for the potential confounder. Accordingly, final models were adjusted for age 
(years), sex (men, women), ethnicity (non-Hispanic White, non-Hispanic Black, all others), 
poverty-income ratio (%), alcohol drinking (yes/no), diabetes (absent/present), BMI 
(normal, overweight, obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic 
blood pressure (mm Hg).
To further ensure that the association is parallel for subgroups, we performed subgroup 
analyses by gender, race/ethnicity, BMI and self-reported cigarettes smoking categories. 
Sample weights that account for the unequal probabilities of selection, oversampling, and 
nonresponse in the NHANES survey were applied for all analyses. Analyses were conducted 
using SAS (version 9.3, SAS Institute, Cary, NC) software. Standard errors were estimated 
using the Taylor series linearization method.
3. Results
Table 1 presents the baseline characteristics of the study population with CRP levels < 10 
mg/L. The study population was primarily non-Hispanic white (72.9%). Approximately one-
half (50.5%) were never smokers, and the remainders were former smokers (21.7%) and 
current cigarettes smokers (27.8%). The arithmetic mean of serum cotinine level was 74.2 
ng/mL.
Tables 2 and 3 present the weighted percentiles and means of individual and the summed 
LMW urinary OH-PAH biomarkers used in the final analysis with CRP and total WBC 
count, respectively. Correlations between pairwise combinations of all eight urinary 
biomarkers (results not shown in a table), were statistically significant, with Pearson 
correlation coefficients that ranged from 0.41 to 0.93.
Table 4 presents the results of the linear regression analyses measuring the association 
between urinary OH-PAH levels, serum CRP and total WBC count. Urinary levels of OH-
PAH were positively associated with serum CRP levels independent of potential 
confounders. All the associations were statistically significant except for 1-
hydroxynaphthalene, 3-hydroxyphenanthrene and 1-hydroxypyrene. Similarly urinary levels 
of OH-PAH were positively associated with total WBC count independent of potential 
confounders. The results of our stepwise linear regression (not presented in a table) showed 
a positive association between serum cotinine and total WBC count [unadjusted odds ratio 
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(95% C.I) 2.99 (1.48, 4.50)]. Serum cotinine showed less strong association with total WBC 
count [unadjusted odds ratio (95% C.I) 0.002(−0.001, 0.005)].
Table 5 presents the odds ratio of the association between urinary levels of OH-PAH and 
high CRP, defined as CRP levels ≥3 mg/L. Overall, urinary levels of OH-PAH were 
positively associated with high CRP in the multivariable adjusted models. Using urinary 
OH-PAH levels as continuous variables, the observed associations were still positive. 
Although positive, the associations between urinary 3-hydroxyphenanthrene and serum CRP 
were not statistically significant.
Table 6 presents the odds ratios of the association between urinary levels of OH-PAH and 
high WBC count, defined as total WBC count in the 95th percentile of the study population. 
Similar to the results for CRP, urinary levels of OH-PAH were positively associated with 
high total WBC count in the multivariable adjusted models. Using urinary OH-PAH levels 
as continuous variables, the observed associations were still positive. Although positive, the 
associations between urinary 1-hydroxyphenanthrene and 3-hydroxyphenanthrene and total 
WBC were not statistically significant.
Table 7 investigates several types of potential confounding. Overall, consistent with the 
findings for the whole cohort, we found that higher urinary levels of summed LMW PAH 
biomarkers were positively associated with high CRP and high total WBC count within 
these stratified subgroups. Compared to females, urinary biomarkers of LMW PAH showed 
stronger association with serum CRP and high total WBC count among males. Compared to 
non-smokers, summed urinary biomarkers of LMW PAH showed stronger association with 
high total WBC count among current cigarettes smokers. Although in the positive direction, 
some of the odds ratios failed to reach the conventional levels of statistical significance. P-
interaction values for cross-product terms between urinary OH-PAH levels and stratifying 
variables were all >0.15 except for gender (P = 0.001) in the CRP analysis and (P = 0.003) 
in the WBC analysis.
4. Discussion
In a multiethnic sample of US adults, we found that higher levels of urinary PAH 
biomarkers were positively associated with high serum CRP levels and total WBC count, 
independent of surveyed cigarettes smoking status, serum cotinine and other potential 
confounders. The association was stronger for the low molecular weight PAH biomarkers, 
compared to 1-hydroxypyrene, a urinary metabolite of the higher molecular weight PAH 
pyrene.
Researchers have examined PAHs directly in the blood and tissues of experimental animals, 
and in humans. The most commonly used biomarkers of PAH exposure are urinary OH-
PAH. Urinary OH-PAH has been found to correlate well with levels of exposure to PAHs in 
the general population (Castano-Vinyals et al., 2004). In addition, there is an evidence that 
the additional effect of human occupational exposures can be detected, independent of 
cigarette smoking (Ciarrocca et al., 2013).
Alshaarawy et al. Page 6
Environ Res. Author manuscript; available in PMC 2015 October 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Humans are usually exposed to PAHs in either a gas or particulate phase. PAHs with the 
lower molecular weight (naphthalene, fluorene, and phenanthrene) are more abundant in the 
gas phase and are absorbed mainly through inhalation (Maliszewska-Kordybach, 1999). In 
contrast, PAHs with higher molecular weight (pyrene) have higher vapor pressure and are 
found in a particulate form (Maliszewska-Kordybach, 1999). They can be absorbed through 
ingestion, skin contact and inhalation (Elovaara et al., 1995; Warshawsky, 1999).
The mechanisms underlying the positive association between urinary PAH biomarkers and 
serum CRP and total WBC count remain unknown. Several in-vitro and animal studies have 
reported a positive association between exposure to PAHs and systemic inflammation 
(Albert, 1977; Penn, 1981; Curfs, 2005; Jeng, et al., 2011). Upon exposure to PAHs, 
detoxification occurs, leading to the formation of highly reactive intermediates that can 
interact with the DNA, forming PAH–DNA plaques in animal arteries (Curfs et al., 2005; 
Jeng, 2011). Several studies have suggested that PAHs might exert this atherogenic effect 
via stimulation of an inflammatory process involving an increased influx of 
proinflammatory cells into these plaques (Curfs, 2005).
Stratifying by gender, the positive association between urinary LMW PAH biomarkers and 
serum CRP ≥3 mg/L and total WBC above the 95th percentile was found to be stronger in 
males when compared to females, suggesting possible gender differences. Different gender-
specific effects of environmental pollutants with outcomes such as inflammatory markers 
have been previously reported by others (Künzli et al., 2005). Hoffman et al. have reported a 
positive association between high levels of urban air pollution and systemic inflammatory 
markers in men (Hoffmann et al., 2009). Different sources and patterns of exposure could 
explain the reported gender differences. In addition, endogenous estrogen and post-
menopausal hormone replacement therapy (Störk, 2008) have been shown to alter plasma 
levels of a variety of cytokines and inflammatory markers, possibly contributing to the 
observed effect modification (Wong, 2008). It is also possible that hormonal differences in 
the way in which men and women metabolize PAHs may explain this observation. PAHs are 
known to be metabolized by cytochrome P450 (Kleiner et al., 2004). It has been shown that 
women have increased lung expression of CYP enzymes compared with men which is 
related to estrogen (Mollerup et al., 1999; Han et al., 2005). Consequently, accelerated 
breakdown of PAHs in the lungs may potentiate the pulmonary response to PAHs in females 
while reducing the circulating PAH concentrations (Van Winkle et al., 2002).
Only two human studies have investigated the association between PAH exposure and 
serum inflammatory markers, and the results were inconsistent. In a study of 999 
participants using NHANES 2003–2004, higher exposure to PAHs was associated with 
elevated levels of serum CRP (Everett et al., 2010). However, in a study of participants in 
NHANES 2001–2004, urinary levels of OH-PAH were not associated with other serum 
inflammatory markers such as total WBC count (Clark III et al., 2012). The differences in 
the results may be partly due to the fact that some NHANES data on PAHs were withdrawn 
(and re-released) due to inconsistencies in the laboratory methods used in 2001–2002 and 
2003–2004 data cycles. The re-release of the data provides an important opportunity for 
updated analysis. In addition, previous studies included participants with CRP levels of 
higher than 10 and total WBC count higher than 12,000 cells/µL, where infection or 
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autoimmune diseases might have confounding effects. Also adjustment for major 
confounders known to interact with inflammatory markers such as alcohol drinking and total 
cholesterol and socio-economic status, and stratifying by major characteristics of the study 
population were not performed in previous studies.
The current study used merged data from NHANES 2001–2002, 2003–2004 and 2005–
2006. The strengths of the study include the relatively large multiethnic sample of the US 
adults, the high quality of NHANES data due to standardized data collection and the ability 
to adjust for potential confounders and to stratify by major sociodemographic 
characteristics. In addition, we investigated the association between PAH exposure and 
serum CRP and total WBC count, independent of the health effects of cigarettes smoking, 
by adjusting for serum cotinine, an objective measure of cigarette smoke exposure in 
addition to stratifying by self-reported smoking status. Cotinine is the principal metabolite of 
nicotine. (Benowitz et al., 1983) Serum cotinine is considered a more precise measure of 
exposure to cigarette smoking when compared to self-reported smoking status, (Perezstable 
et al., 1995; Gorber et al., 2009) and is considered an accurate biomarker of second-hand 
smoke exposure (Benowitz, 1996).
The study has limitations as well. The cross-sectional nature of NHANES does not allow us 
to draw temporal or causal inferences regarding the relationship between PAHs and serum 
inflammatory markers. Urinary PAH biomarker measurements reflect recent exposure to 
PAHs and do not reflect differences between the current exposure sources and the past 
exposure sources for each subject. Due to its short half-life, serum cotinine also reflects 
recent exposure to tobacco smoke. However, these biases are likely to be non-differential 
biases, which would minimize any associations observed.
In conclusion, lower background exposure to PAHs was found to be positively associated 
with serum markers of systemic inflammation i.e. serum CRP and total WBC count 
independent of potential confounders. The association was more evident in adult males 
when compared to females. Active cigarettes smoking appears to play a significant role in 
the association of urinary OH-PAH and total WBC count, yet the association persists after 
adjustment for serum cotinine and self-reported smoking status. There is a need to replicate 
these findings in future prospective studies with adequate sample size
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Table 1
Baseline characteristics of the study population with measured urinary levels of OH-PAH and CRP≤10 mg/L.
Characteristics Mean values (Std error of mean) or
sample size (weighted percentages)
Women (%) 1136 (47.7)
Age (years) 40.9 (0.34)
Race/Ethnicity (%)
  Non-Hispanic Whites 1200 (72.9)
  Non-Hispanic Blacks 463 (10.0)
  Others 691 (17.1)
Education categories (%)
  Less than high school 547 (14.2%)
  High school 541 (24.2)
  Above high school 1266 (61.6)
Below poverty level (%) 392 (12.1)
Smoking categories (%)
  Never 1229 (50.5)
  Former smokers 501 (21.7)
  Current smokers 624 (27.8)
Alcohol drinking (%)
  Yes 1731 (77.2)
Body mass index (%)
  Normal weight (<25.0 kg/m2) 784 (36.5)
  Overweight (25.0–29.9 kg/m2) 827 (32.9)
  Obese (≥ 30.0 kg/m2) 743 (30.6)
Serum cotinine (ng/mL) 74.2 (4.25)
Total cholesterol (mg/dL) 201.6 (1.43)
Systolic blood pressure (mmHg) 119.1 (0.47)
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Table 4
Linear regression: association between urinary OH-PAH levels (ng/g creatinine) and serum CRP (mg/L) and 
total WBC count (cells/µL).
Chemicals Multivariable change in CRP* Multivariable change in total WBC count*
Sample size Log OH-PAH Sample size Log OH-PAH
1-Hydroxynaphthalene 2480 0.07(−0.01, 0.14) 2620 89.7(8.9, 170.5)
2-Hydroxynaphthalene 2488 0.14(0.04, 0.25) 2628 229.2(103.2, 355.3)
2-Hydroxyfluorene 2465 0.16(0.06, 0.26) 2604 310.1(190.1, 430.0)
3-Hydroxyfluorene 2450 0.10(0.02, 0.18) 2588 235.9(135.9, 335.9)
1-Hydroxyphenanthrene 2469 0.21(0.10, 0.33) 2610 132.4(19.5, 245.3)
2-Hydroxyphenanthrene 2448 0.19(0.01, 0.36) 2587 213.6(117.3, 309.9)
3-Hydroxyphenanthrene 2444 0.05(−0.06, 0.17) 2585 199.8(81.8, 317.7)
1-Hydroxypyrene 2461 0.11(−0.004, 0.21) 2600 144.5(53.8, 235.2)
Summed LMW PAH biomarkers 2369 0.15(0.04, 0.25) 2505 186.0(73.0, 299.0)
*Adjusted for age (years), sex (male/female), BMI (Normal weight/overweight/obese), race (non-Hispanic White/non-Hispanic Black/all others), 
alcohol drinking (yes/no), poverty-income ratio, total cholesterol (mg/dL), serum cotinine (ng/mL), diabetes mellitus (absent/present) and systolic 
blood pressure (mm Hg).
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Table 7
Logistic regression: association between summed urinary biomarkers of LMW PAH (ng/g creatinine) and 
serum inflammatory markers by sociodemographic characteristics.
Subgroups Multivariable
odds ratio of
CRP ≥3 mg/L*
P
interaction
Multivariable odds
ratio of total WBC
count in the 95th
percentile*
p-
interaction
Gender 0.001 0.003
Female 1.08(0.93, 1.25) 1.21(0.95, 1.55)
Male 1.32(1.12, 1.55) 1.90(1.41, 2.56)
Race-ethnicity 0.29 0.29
Non-Hispanic white 1.16(1.00, 1.34) 1.34(1.10, 1.64)
All others 1.18(0.98, 1.41) 1.27(0.92, 1.74)
Body mass index 0.55 0.71
Normal weight 1.32(0.98, 1.76) 1.41(1.03, 1.93)
Overweight 1.11(0.89, 1.38) 1.38(0.98, 1.94)
Obese 1.09(0.93, 1.28) 1.28(1.00, 1.65)
Smoking 0.27 0.35
Never smokers 1.21(0.98, 1.50) 1.21(0.88, 1.68)
Former smokers 1.03(0.88, 1.19) 1.15(0.83, 1.59)
Current smokers 1.10(0.81, 1.49) 1.78(1.28, 2.48)
*Adjusted for age (years), sex (male/female), ethnicity (non-Hispanic White/ non-Hispanic Black/all others), poverty-income ratio, alcohol 
drinking (yes/no), diabetes (absent/present), BMI (normal/overweight/obese), total cholesterol (mg/dL), serum cotinine (ng/mL) and systolic blood 
pressure (mm Hg), except for stratified variables.
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